Benzinga | May 26, 2021 08:04AM EDT

Pacira BioSciences Says Phase 3 STRIDE Study Did Not Demonstrate Statistical Significance For Primary Endpoint Of Pain Reduction From 0 To 96 Hours For EXPAREL Vs Bupivacaine HCL